Companion Animal Drugs

Global Companion Animal Drugs Market to Reach US$28.9 Billion by 2030

The global market for Companion Animal Drugs estimated at US$20.3 Billion in the year 2024, is expected to reach US$28.9 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Companion Animal Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$13.5 Billion by the end of the analysis period. Growth in the Companion Animal Vaccines segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 9.8% CAGR

The Companion Animal Drugs market in the U.S. is estimated at US$5.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.0 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Companion Animal Drugs Market - Key Trends & Drivers Summarized

What is Fueling the Rising Demand for Companion Animal Drugs?

The surge in demand for companion animal drugs is primarily driven by the growing humanization of pets. As pet owners increasingly view their animals as family members, there is a stronger emphasis on maintaining their health, longevity, and overall well-being. This shift has led to a greater willingness to invest in advanced veterinary pharmaceuticals, including vaccines, anti-infectives, and parasiticides. Additionally, the increasing incidence of zoonotic diseases has raised concerns about pet health, prompting pet owners and veterinary professionals to prioritize preventative care. Governments and regulatory bodies worldwide are also stepping up their efforts to promote animal health through more stringent policies and incentives for veterinary drug development. As a result, pharmaceutical companies are heavily investing in research and development to introduce innovative, effective, and safe medications for companion animals.

How Are Technological Advancements Shaping the Market?

Innovation in veterinary medicine is a key driver of market expansion. Advances in biotechnology and genomic research are leading to the development of more precise and targeted therapies for companion animals. For example, the emergence of monoclonal antibodies for treating conditions such as osteoarthritis in dogs is revolutionizing the treatment landscape. Additionally, telemedicine and digital pet health tracking solutions are enhancing the way veterinarians diagnose and prescribe medications. The adoption of precision medicine and personalized veterinary treatments is also becoming a prominent trend, allowing pet owners to access tailored therapeutic options for their animals. Furthermore, the increasing integration of artificial intelligence (AI) in veterinary diagnostics is improving drug efficacy and disease management, providing a significant boost to the market. These technological breakthroughs are not only improving animal health outcomes but also creating new revenue streams for pharmaceutical companies and veterinary clinics alike.

What Role Do Consumer Trends and Pet Ownership Patterns Play?

The changing demographics of pet ownership are significantly influencing the demand for companion animal drugs. With urbanization on the rise, there is an increasing preference for smaller pets such as dogs, cats, and exotic animals that require regular medical care. Millennials and Gen Z pet owners, in particular, are more inclined to spend on premium healthcare services for their pets, including specialized drugs and wellness products. The trend of pet insurance is also gaining traction, facilitating higher spending on veterinary pharmaceuticals. Additionally, rising disposable incomes in developing economies are leading to an uptick in pet ownership rates, further fueling market growth. The shift toward organic and natural pet products is another factor shaping industry trends, as consumers seek safer and more sustainable treatment options for their pets. As awareness around pet health and wellness continues to grow, the demand for high-quality, scientifically backed veterinary drugs is expected to escalate.

What Are the Key Drivers Behind Market Growth?

The growth in the Companion Animal Drugs market is driven by several factors, including rising pet ownership rates, increasing veterinary expenditure, and advancements in veterinary pharmaceuticals. A growing number of regulatory approvals for novel drugs is expanding treatment options for a range of conditions such as infectious diseases, chronic illnesses, and behavioral disorders. The prevalence of lifestyle-related diseases in companion animals, such as obesity and diabetes, is also leading to a surge in demand for prescription medications. Additionally, the expansion of e-commerce platforms has made veterinary pharmaceuticals more accessible to pet owners, further driving sales. The rising trend of adopting rescue animals and shelter pets is another key contributor, as these animals often require extensive medical care. Furthermore, the increasing awareness and implementation of One Health initiatives, which emphasize the interconnectedness of human and animal health, are encouraging governments and private organizations to invest in companion animal healthcare solutions. As the industry continues to evolve, the synergy between biotechnology, pet health awareness, and digital veterinary services is expected to shape the future of companion animal drug development and distribution.

SCOPE OF STUDY:

The report analyzes the Companion Animal Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Companion Animal Drugs, Companion Animal Vaccines, Medicated Feed Additives); Animal Type (Dogs, Cats, Horses, Other Animal Types); Administration Route (Oral Administration, Injectable Administration, Topical Administration, Other Administration Routes); Distribution Channel (Veterinary Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, E-commerce Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Aratana Therapeutics (now part of Elanco)
• Bayer AG
• Bimeda, Inc.
• Boehringer Ingelheim
• Calier
• Ceva Santé Animale
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Eltech K-Laser s.r.l
• Matsun Nutrition
• Merck & Co., Inc.
• Merial (now part of Boehringer Ingelheim)
• Norbrook Laboratories Ltd
• Nutreco N.V.
• Perrigo Company plc
• Synotic (VetOne)
• Vetbiolix
• Vetoquinol S.A.
• Virbac
• Zymox (Pet King Brands)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.